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Background. AMP-activated protein kinase (AMPK) is a heterotrimeric enzyme that is evolutionarily conserved from yeast to
mammals and functions to maintain cellular and whole body energy homeostasis. Studies in experimental animals
demonstrate that activation of AMPK in skeletal muscle protects against insulin resistance, type 2 diabetes and obesity. The
regulatory c3 subunit of AMPK is expressed exclusively in skeletal muscle; however, its importance in controlling overall AMPK
activity is unknown. While evidence is emerging that gamma subunit mutations interfere specifically with AMP activation,
there remains some controversy regarding the impact of gamma subunit mutations [1–3]. Here we report the first gain-of-
function mutation in the muscle-specific regulatory c3 subunit in humans. Methods and Findings. We sequenced the exons
and splice junctions of the AMPK c3 gene (PRKAG3) in 761 obese and 759 lean individuals, identifying 87 sequence variants
including a novel R225W mutation in subjects from two unrelated families. The c3 R225W mutation is homologous in location
to the c2R302Q mutation in patients with Wolf-Parkinson-White syndrome and to the c3R225Q mutation originally linked to an
increase in muscle glycogen content in purebred Hampshire Rendement Napole (RN
-) pigs. We demonstrate in differentiated
muscle satellite cells obtained from the vastus lateralis of R225W carriers that the mutation is associated with an approximate
doubling of both basal and AMP-activated AMPK activities. Moreover, subjects bearing the R225W mutation exhibit a ,90%
increase of skeletal muscle glycogen content and a ,30% decrease in intramuscular triglyceride (IMTG). Conclusions. We
have identified for the first time a mutation in the skeletal muscle-specific regulatory c3 subunit of AMPK in humans. The
c3R225W mutation has significant functional effects as demonstrated by increases in basal and AMP-activated AMPK activities,
increased muscle glycogen and decreased IMTG. Overall, these findings are consistent with an important regulatory role for
AMPK c3 in human muscle energy metabolism.
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Increased Glycogen and Decreased Triglyceride in Skeletal Muscle. PLoS ONE 2(9): e903. doi:10.1371/journal.pone.0000903
INTRODUCTION
AMP-activated protein kinase (AMPK) is a serine/threonine
kinase that is evolutionarily conserved from yeast to mammals and
functions as a highly responsive energy sensor in cells [4–7]. It acts
both centrally and peripherally to coordinate multiple inputs from
various hormones, peptides and nutrients to maintain overall
energy homeostasis. In response to cellular stress in the periphery,
AMPK inhibits anabolic pathways and stimulates catabolic
pathways to restore cellular energy charge. In vitro and exper-
imental animal studies have demonstrated that altered activity of
AMPK has significant implications for a number of cardiovascular
risk factors, including type 2 diabetes [4–6]. In skeletal muscle,
AMPK activation stimulates glucose uptake, fatty acid uptake and
oxidation, and mitochondrial biogenesis [5]. Thus AMPK
activation in skeletal muscle protects against the development of
insulin resistance, type 2 diabetes and obesity [8–11].
AMPK has a heterotrimeric structure and is composed of an a-
catalytic, a b-regulatory and a c-regulatory subunit. The a-
catalytic subunit has two isoforms (a1, a2), the b-regulatory subunit
has two isoforms (b1, b2), and the c-regulatory subunit has three
isoforms (c1, c2, c3) [12,13]. Figure 1 depicts the three c isoforms
and their structural characteristics. The various isoforms of each
subunit are encoded by distinct genes, with alternative promoters
and splice variants, adding to genetic and post-translational
complexities [5]. Most isoforms are expressed to some extent in
all tissues, although mRNA expression data indicate that the c3
subunit is more abundant in skeletal muscle than in any other
tissue [14]. The relative proportions of the c subunits in human
skeletal muscles are as yet unknown. Several exercise studies in
humans have measured c subunit protein levels in the vastus lateralis
muscle. In these studies, protein levels were expressed as
percentage of sedentary controls, pretraining values, or untrained
muscles as opposed to absolute relative values [15–17]. A more
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AMPK complex combinations are expressed in human vastus
lateralis: a1/b2/c1, a2/b2/c1 and a2/b2/c3 [18] . The only
heterotrimer shown to be phosphorylated and activated during
high intensity exercise was the complex containing the c3 isoform.
The activity associated with the other two heterotrimers either
remained unchanged or decreased during exercise [18]. The c2
long and short isoforms (c2L and c2S, respectively) result from
alternative splicing of a common transcript in heart and other
tissues [19–21]. While both long and short isoforms are expressed
in heart, c2S is predominant in skeletal muscle [19].
To date the only published mutations in the AMPK genes in
humans are in the c2-regulatory subunit, the predominant c
isoform in cardiac muscle. While AMPK activity stimulates fatty
acid oxidation, glucose uptake and glycolysis in the heart, its
regulation is complex, and still not well understood [2,3,22]. At
least six different missense mutations within the CBS domains of c2
have been shown to cause the excess storage of glycogen in
pronounced glycogen-associated vacuoles[23]. This excess storage
of glycogen results in a complex phenotype, including Wolf-
Parkinson-White (WPW) syndrome, conduction system disease
and cardiac hypertrophy [21,24,25]. In purebred Hampshire
Rendement Napole (RN) pigs, a naturally occurring R225Q
mutation in the c3 subunit of AMPK was identified and linked to
increased glycogen storage in skeletal muscle [26] and to increased
resynthesis of glycogen after exercise when R225Q AMPKc3 is
overexpressed in transgenic mice [7].
In the context of our ongoing goal of identifying genes that
underlie predisposition for diabetes and obesity, we searched for
genetic variation in human PRKAG3. Of the 24 novel coding
variants identified, we focused on the R225W mutation due to the
established importance of the mutation in porcine AMPK c3 and
the homologous mutations in the c2 subunit of human AMPK. We
determined the functional significance of this mutation in
differentiated muscle cells from the vastus lateralis of R225W
carriers compared to matched controls.
Here we describe a previously unreported R225W mutation in
the human AMPK c3 gene, PRKAG3, found in two independent
kindreds. We show that the R225W mutation causes increased
basal and AMP-activated AMPK activity, as well as increased
muscle glycogen storage and decreased intramuscular triglyceride
(IMTG).
METHODS
Subjects and Sequence Analysis
The coding exons and splice junctions of the human AMPK c3
gene (NCBI accession no. NM_017431) were resequenced in
obese Caucasian subjects from the Ottawa Hospital Weight
Management Clinic and in lean healthy Caucasian individuals
who participated in a study of leanness at the University of Ottawa
Heart Institute. The cohorts consisted of 761 obese subjects with
a mean BMI of 39.9 kg/m
2 and.90
th percentile adjusted for age
and sex, and 759 lean subjects with a mean BMI of 20.1 kg/m
2
and,25
th percentile adjusted for age and sex. The study was
approved by the institutional review boards of the University of
Ottawa Heart Institute and the Ottawa Hospital. Informed written
consent was obtained from all participants. A total of 58 genes
were sequenced as part of this study and detailed findings have
been presented elsewhere [27]. Selection criteria for our patient
population as well as methods for DNA isolation, sequencing and
data analysis have been described previously [28].
Predictions of the possible functional implications of the variants
were made using PolyPhen (http://genetics.bwh.harvard.edu/
pph/) and SIFT (http://blocks.fhcrc.org/sift/SIFT.html) pro-
grams [29,30]. The R225W variant, which is found in the second
CBS domain (Figure 1), was identified to be functionally damaging
by both programs. This variant was intriguing since it is analogous
to the R225Q mutation causing increased muscle glycogen
content in pigs, as well as having the same amino acid location
as the mutations in the human c2 subunit that are known to alter
AMPK protein function and cause Wolf-Parkinson-White syn-
drome. We thus contacted subjects that were identified as carrying
the R225W mutation in the initial study cohorts, and screened
their available family members for further study (Figure 2). The
region of the AMPKG3 gene with the R225W variation was
sequenced in DNA samples from family members to determine
whether they carried the same variation. Subject characteristics
are described in Table 1.
Skeletal Muscle Biopsies and Cell Culture
Five subjects with the R225W mutation and five control subjects
were matched for gender, age, weight, BMI, as well as amount and
intensity of self-reported weekly physical activity. These subjects
refrained from physical activity for three days prior to undergoing
Figure 1. c subunit isoforms showing the 4 tandem repeats of CBS domains responsible for AMP and ATP binding. Locations of the human
R225W and the porcine R225Q mutations in the c3 subunit as well as the R302Q and R61Q mutations in the c2 long and short forms, respectively, are
indicated. Figure adapted from [12].
doi:10.1371/journal.pone.0000903.g001
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fast. Percutaneous skeletal muscle biopsies of the vastus lateralis
muscle were obtained from R225W carriers and their matched
controls using a 5 mm Bergstrom needle (Opitek) under local
anaesthesia with 1% lidocaine. Vastus lateralis is commonly selected
for studies of human muscle metabolism and was chosen for biopsy
in the current study due to the demonstrated importance of the c3
subunit in this muscle [18]. A 10 mg sample of the biopsy was
flash frozen in O.C.T. compound for muscle fiber typing, glycogen
content determination and IMTG determination. A 25 mg sample
of tissue was subjected to trypsin digestion and cells were grown to
,70% confluency in Ham’s F10 media (supplemented with 1%
antibiotic-antimycotic, 2.5 mg/mL gentamycin, 12.4% FBS,
0.41 mg/mL BSA, 826 nM dexamethazone, 8.3 ng/mL epider-
mal growth factor, 0.41 mg/mL fetuin, and 25 pmol insulin).
Isolation of satellite cells was achieved via immuno-sorting using
primary anti-5.1H11 (Developmental Studies Hybridoma Bank)
and secondary MACS goat anti-mouse IgG microbeads. After the
suspension was passed through a magnetic field, labelled cells were
isolated, eluted and then grown up in culture. Upon reaching 80%
confluency, cells were differentiated for ,10 days in Dulbecco’s
modified Eagle’s medium (supplemented with 2% horse serum,
1% antibiotic-antimycotic and 2.5 mg/mL gentamycin).
AMPK Isolation
Approximately 10 days after differentiation, myotubes were
incubated on ice while shaking in the presence of lysis buffer
(30 mM HEPES, 2.5 mM EGTA, 3 mM EDTA, 70 mM KCl,
0.1% Nonidet P-40, 20 mM b-glycerophosphate, 20 mM NaF,
2 mM NaPPi, 1 mM Na3VO4, 200 mM PMSF and 1 mM
pepstatin A). Partial purification of AMPK from the cell lysate
was carried out as detailed in [31,32]. The cell lysate was
incubated at a 1:1 ratio with 30% polyethylene glycol 6000 for
1 hour. Resulting purified protein was dissolved in assay buffer
(62.5 mM Na HEPES, 62.5 mM NaCl, 62.5 mM NaF, 6.25 mM
Na pyrophosphate, 1.25 mM EDTA, 1.25 mM EGTA, 1 mM
dithiothreitol, 1 mM PMSF, 5 mg/mL SBTI and 1 mM pepstatin
A) and then quantified using the bicinchoninic assay.
AMPK Activity Determination
The SAMS peptide assay was carried out as detailed in [32,33]
with minor modifications: 13 mL reaction buffer (20 mM HEPES-
NaOH, 0.4 mM dithiothreitol, 0.01% Brij-35 with or without
300 mM AMP), 10 mL of 562 mM SAMS substrate peptide,
10 mCi [
32P]ATP (3000 Ci/mmol), and 6 mg of partially purified
AMPK were incubated with constant shaking at 30uC for
15 minutes. Negative controls consisted of all reagents except
SAMS substrate peptide and AMP. All reactions were carried out
in triplicate. AMPK activity was expressed as pmol of
32P-
radiolabeled phosphate incorporated into the SAMS peptide per
minute per mg of protein.
Figure 2. Families of the two probands with the PRKAG3-R225W mutation. *Subjects who underwent muscle biopsy.
doi:10.1371/journal.pone.0000903.g002
Table 1. Characteristics of PRKAG3-R225W subjects and
controls who underwent muscle biopsy.
......................................................................
R225W (n=5) Controls (n=5)
Age (years) 40.6612.4 42.8612.9
Weight (kg) 82.5623.2 80.9627.1
BMI (kg/m
2)2 9 . 1 69.0 29.2610.3
Total Cholesterol (mmol/L) 5.5460.70 4.5260.66
Body Fat (%) 34.6610.4 35.668.7
Basal Metabolic Rate (kJ) 6773.861201.1 5380.462134.9
HDL-C (mmol/L) 1.2960.26 1.5260.70
LDL-C (mmol/L) 3.2260.47 2.5560.35
TC:HDL 4.4060.71 3.4461.24
Triglycerides (mmol/L) 2.2761.00 1.1160.61
Glucose (mmol/L) 4.9460.61 5.1660.63
Insulin (pmol/L) 54.2610.1 47.4635.8
HbA1C 0.052260.0031 0.054460.0013
Blood chemistry measurements were conducted following an overnight fast.
Means +/2 SD. n=5, Student’s t-test, no significant differences between R225W
and control subjects.
doi:10.1371/journal.pone.0000903.t001
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RNA from muscle biopsy samples was extracted using Trizol
(Invitrogen) and treated with DNaseI (Ambion). cDNA was
generated from 0.5 mg of RNA using random decamer primers
(Ambion) with MMLV reverse transcriptase (Invitrogen). Amplicons
of AMPKG3 and GAPDH genes were cloned into pCR 2.1-TOPO
(Invitrogen).Serialdilutionsoftheseconstructswereused togenerate
standard curves, following assessment of primer efficiency and
analysis of melting curve profiles. Quantitative real-time PCR
analysis was performed in a LightCycler system (Roche) using
FastStart DNA MasterPLUS SYBR Green I kit (Roche). The
primers for real-time PCR were designed using LightCycler Probe
Design Software v1.0 (Roche). Following 30 cycles of amplification
with 1.0 mlo fc D N Aa n d0 . 5mM of F and R primers per reaction,
expression of AMPKG3 was normalized to expression of GAPDH.
Primer sequences: F: 59-CAGAGGACACTATGTCTGG-39 and
R: 59-GCTTGGGATTGAGGACT-39 (AMPKG3), F: 59-GATT-
TGGCCGTATTGGG-39 and R: 59-TCCACGACATACTCA-
GC-39 (GAPDH).
Western Blotting and Densitometry
To determine protein levels of the c3 isoform, the same purified
protein extracts that were used for the AMPK activity assay were
subjected to immunoblotting. Electrophoresis was carried out
using a 12% polyacrylamide gel. Following transfer to nitrocellu-
lose membranes, primary antibodies were incubated at a 1:1000
dilution overnight at 4uC( A M P K c1, AMPKc3 and b-actin
antibodies were from Cell Signaling Technology, Danvers, MA).
The secondary antibody was a peroxidase-conjugated goat anti-
rabbit IgG (Santa Cruz Inc., Santa Cruz, CA) and was incubated at
a 1:500 dilution for one hour at room temperature. For detection,
blots were processed using enhanced chemiluminescence kits
(Amersham Pharmacia; Baie d’Urfe, QC, Canada). b-actin was
used as the loading control and densitometry was carried out to
determine relative protein levels (values expressed as c isoform
integrated densitometry value (IDV) divided by b-actin IDV).
Muscle Glycogen Content Determination
Glycogen content was determined using Periodic Acid Schiff (PAS)
staining.Frozentissueswerecutas10 mm crosssections and mounted
onSuperfrostslides.AfterSchiffstaining,sectionswerecounterstained
with Harris’s hematoxylin. Imaging software (Northern Eclipse) was
usedtoanalyzetissues at2006magnificationwithanAxiophotdigital
light microscope (Axiophot 2, Zeiss, Oberkochen, Germany). 2–3
fields of view in each of 3 sections per patient were analyzed for
glycogen content as a proportion of surface area of each field.
Intramuscular Triglyceride (IMTG) Content
lMTG content was determined using osmium tetroxide (OsO4)
staining. Frozen tissues were cut as 10 mm cross sections and
mounted on Superfrost slides and fixed in 10% neutral buffered
formalin. IMTG was stained black with 1% OsO4 and then cells
were counterstained with hematoxylin and eosin (H&E). Imaging
software (Northern Eclipse) was used to analyze tissues at 2006
magnification with an Axiophot digital light microscope (Axiophot
2, Zeiss, Oberkochen, Germany). 2–3 fields of view in each of 3
sections per patient were analyzed for IMTG content as
a proportion of surface area of each field.
Fiber Typing
Frozen tissues were cut as 10 mm cross sections and mounted on
Superfrost slides. Sections were stained using the Vectastain ABC-
AP kit (Vector Laboratories). Type 1 fibers were identified by
using A4.840 as the primary antibody (Developmental Studies
Hybridoma Bank), which is specific to the C-terminal part of the
beta slow myosin heavy chain in type I skeletal muscle fibers.
Biotinylated goat anti-mouse IgG (BA-9200, Vector Laboratories)
was used as the secondary antibody, and then cells were stained
red using SK-5100 (Vector Laboratories). Type 2a fibers were
identified by using N2.261 as the primary antibody (Developmen-
tal Studies Hybridoma Bank), which is specific to the N-terminal
part of the beta slow myosin heavy chain in adult skeletal myosin
heavy chain type IIA. BA-9200 was used as the secondary
antibody, and then cells were stained blue using SK-5300 (Vector
Laboratories). Type 2b/x fibers were identified as unstained cells.
Fiber type ratios were determined by counting numbers of each
fiber type in 2–3 fields of view in 3 sections per patient.
Statistical Analysis
The management of clinical and genotypic data was carried out
with SAS statistical software (Version 9.1, SAS Institute Inc., Cary,
NC). A one-way ANOVA with Tukey post-test was used to
determine differences in AMPK activity (Figure 3). Student’s t tests
were used to assess mRNA levels, protein levels, glycogen content,
intramuscular triglyceride and fiber type ratio (Figures 4–7).
RESULTS
AMPK c3 Sequence Variants
We sequenced the exons and intron/exon boundaries of PRKAG3,
which codes for the subunit of AMPK that is specific to skeletal
muscle. We studied 761 obese subjects with a mean BMI of
39.9 kg/m
2 and.90
th percentile adjusted for age and gender, and
759 lean subjects with a mean BMI of 20.1 kg/m
2 and,25
th
percentile adjusted for age and gender. We identified 87 genetic
variants in PRKAG3 and its flanking regions. Of the six common
(minor allele frequency.0.05) variants, three were intronic
polymorphisms (IVS2+45, IVS6+31 and IVS10+85), one was
a synonymous variant (G180G), and two were non-synonymous
variants (P71A and R340W). The 81 rare variants included one
Figure 3. Basal and AMP-activated AMPK activities in differentiated
skeletal muscle cells from R225W carriers and matched control
subjects. Means +/2 SD. n=3, One-way ANOVA, Tukey post-test,
*p=0.015, **p=0.001.
doi:10.1371/journal.pone.0000903.g003
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10 synonymous and 16 nonsynonymous coding variants, one
frameshift mutation that leads to a stop codon and two SNPs in the
39 UTR. The frequency and functional prediction for the coding
variants are outlined in Table 2. Of the 30 coding PRKAG3
variants observed in this study, 24 were not listed in the current
SNP database (dbSNPbuild126). Computational predictions of the
severity of missense substitutions were made using PolyPhen [29]
and SIFT [30].
Given the established importance of homologous mutations in
Rendement Napole (RN
-)pigs (c3R225Q) [26,34,35] and in the c2
subunit (R302Q/R61Q) in human patients [21], we pursued the
functional significance of the novel R225W mutation identified in
two unrelated subjects. A total of 11 subjects from the two families
were screened for the R225W mutation. Two family members in
the first family and three family members in the second family
were observed to carry the mutation (Figure 2). Other sequence
variants that are predicted to have functional implications
according to PolyPhen and SIFT are shown in Table 2. Of
interest are variants M197T, I269T, R307C and R340Q, all of
which occur at similarly low frequencies in our cohorts.
Characteristics of R225W and Matched Control
Subjects
The five carriers of the R225W variant were matched with control
subjects on the basis of gender, age, weight, and BMI. The R225W
carriers and control subjects were also well-matched for amount and
intensity of self-reported weekly physical activity. Two brothers of
the proband in the first family, and the sister and daughter of the
proband in the second family consented to muscle biopsies and were
includedinthestudy(Figure2).Nosignificantdifferenceswerenoted
in fasting values for plasma lipids, glucose, insulin,or HbA1C in this
small cohort (Table 1). During a hyperinsulinemic glucose clamp
study,the rateofglucoseinfusionrequiredto maintaineuglycemiain
the last hour of the clamp was somewhat higher in the 2 carriers of
the R225W variant as compared to 2 closely matched controls but
did not reach a nominal standard of significance (7.360.8 vs.
5.462.4 ml/kg/min, p=0.16).
Figure 4. Relative protein levels of the c1 (A) and c3 (B) isoforms in
differentiated skeletal muscle cells from R225W carriers and matched
control subjects. The integrated densitometry value (IDV) for each c
subunit was divided by the IDV of the loading control, b-actin. Means +/
2 SD. n=2–4, Student’s t-test, p=0.389 (A), p=0.229 (B).
doi:10.1371/journal.pone.0000903.g004
Figure 5. Glycogen content of vastus lateralis for R225W and control
subjects. Muscle sections were prepared and stained with PAS, as
described in the methods section (A: control, B: R225W). C:
quantification of glycogen content via imaging software. Means +/2
SD. n=5, Student’s t-test, **p=0.002.
doi:10.1371/journal.pone.0000903.g005
Human R225W AMPKc3 Mutation
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We determined that the R225W mutation had an overall effect on
AMPK activity. Myocytes derived from vastus lateralis biopsies were
immunopurified and differentiated into myotubes, following which
total AMPK activity was assayed using the ‘gold-standard’ SAMS
peptide assay [32,33] in purified protein extracts. Results demon-
strated that the basal (p=0.015) as well as the AMP-activated
(p=0.001) AMPK activities in subjects with the R225W mutation
were two-fold higher compared to that found in controls (Figure 3).
Control subjects exhibited a 0.054 pmol/min/mg mean increase in
activity upon AMP-stimulation, whereas R225W carriers showed
a mean increase of 0.108 pmol/min/mg, representing a 65% and
a 58% increase from basal activity, respectively. Although R225W
carriers demonstrate twice the AMP-stimulated AMPK activity of
control subjects, the similar percent increases indicate that R225W
AMPK is likely activated by AMP with a similar magnitude to
control AMPK. R225W AMPK is therefore not constitutively active
or AMP-independent, as it is able to be further activated by AMP.
Expression of AMPK c Isoforms
AMPKc3 mRNA levels in skeletal muscle biopsy samples were
detected by RT-PCR analysis. There was no difference in AMPKc3
mRNA levels between R225W carriers and control subjects
(p=0.083, 2-tailed t-test). AMPKc1 and c3 protein levels were
detected by Western blotting in the same purified protein extracts as
used for the AMPK activity assay. b-actin was used as the loading
control and densitometry was carried out to determine relative
protein levels. There were no differences in either AMPKc1 or c3
protein levels between R225W carriers and control subjects (p=
0.389and p=0.229,respectively)(Figure 4aandb).Importantly, the
only three complexes that normally contribute to AMPK activity in
human vastus lateralis are a1b2c1, a2b2c1 and a2b2c3 [18]. We believe
that the R225W variant is affecting AMPK activity without affecting
the level of transcription or translation of the PRKAG3 gene.
Skeletal Muscle Glycogen Content
To determine the effect of the R225W mutation on skeletal muscle
glycogen content, we used Periodic Acid Schiff (PAS) staining of
cryo-sectioned vastus lateralis muscle. As shown in Figure 5, muscle
of R225W carriers had approximately 90% more muscle glycogen
content than controls (p=0.002). This result was expected as the
Hampshire RN
- pigs carrying the R225Q c3AMPK mutation have
increased muscle glycogen content [26].
Intramuscular Triglyceride (IMTG) Content
We hypothesized that IMTG would be reduced in skeletal muscle
of subjects with the R225W variant, given observations in trans-
genic mice expressing the homologous mutation in the AMPK c3
gene and fed a high fat diet [7]. Osmium tetroxide (OsO4) staining
of sections of the vastus lateralis muscle indicated lower IMTG levels
in the R225W carriers as compared to matched controls
(p=0.032) (Figure 6).
Figure 6. Intramuscular triglyceride content of vastus lateralis for
R225W and control subjects. Muscle sections were prepared and
stained with OsO4, as described in the methods section (A: control, B:
R225W). C: quantification of IMTG via imaging software. Means +/2 SD.
n=4, Student’s t-test, *p=0.032.
doi:10.1371/journal.pone.0000903.g006
Figure 7. Fiber type ratios of vastus lateralis for R225W versus control
subjects, expressed as percentage of each fiber type. Means +/2 SD.
n=5, Student’s t-test for each fiber type, no significant differences
between R225W and control subjects (Type 1: p=0.992, Type 2a:
p=0.896, Type 2b/x: p=0.834).
doi:10.1371/journal.pone.0000903.g007
Human R225W AMPKc3 Mutation
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Finally, we determined whether or not there were differences in
muscle fiber type composition in the biopsied muscle. Immuno-
histochemistry of the sections revealed a similar proportional
distribution of fiber types in subjects with the R225W mutation
compared to controls (Figure 7). Fiber type ratio is an important
measure due to its influence on muscle glycogen content and
IMTG content. Since there are no differences in fiber type ratio
between R225W subjects and controls, differences in glycogen and
IMTG cannot be attributed to fiber type composition.
DISCUSSION
AMPK is widely recognized as a key metabolic regulator of energy
expenditure in peripheral tissues and of energy intake in the
hypothalamus. In this study we focused on the functional
importance of a rare mutation in PRKAG3 encoding the AMPK
regulatory c3 subunit that is expressed exclusively in skeletal
muscle. While the functions of the three AMPK subunits have not
been fully characterized, it is becoming increasingly clear that the
c subunit is a major regulator of holoenzyme activity [4–6,22].
The c subunit is thought to be involved in AMP binding, and in
the regulation of glycogen content as variants in its CBS domains
affect glycogen metabolism in skeletal and cardiac muscle
[19,23,25,26,36]. This is the first report of functional effects of
nonsynonymous sequence variants in the c3 subunit in humans.
We have demonstrated that the R225W mutation increases basal
and AMP-activated AMPK activities in differentiated muscle cells
obtained from the vastus lateralis of carriers (Figure 3), and that c1
and c3 protein levels are unchanged in R225W carriers (Figure 4).
Normally in human vastus lateralis, the complexes that contribute to
AMPK activity are a1b2c1, a2b2c1 and a2b2c3 [18]. Future studies
will need to assess the subunit combinations that contribute to
AMPK activity in R225W carriers. We have also demonstrated
that R225W results in increased skeletal muscle glycogen content
(Figure 5) and decreased IMTG content (Figure 6), while there was
no change in muscle fiber type composition (Figure 7).
Further studies are required to characterize the effects of
R225W on metabolic responses to challenges such as acute and
chronic exercise. However, given the literature on Hampshire RN
-
Table 2. Coding variants in the PRKAG3 gene observed in this study.
..................................................................................................................................................
Variant Allele MAF (Obese) MAF (Lean) S/NS Functional Prediction
PolyPhen SIFT
E70E G.A 0 0.001 S - -
P71A (rs692243) C.G 0.179 0.160 NS possibly damaging tolerated
E76Q G.C 0 0.001 NS benign tolerated
E85E G.A 0.001 0 S - -
T87T C.T 0.003 0.003 S - -
D103G A.G 0.001 0 NS benign tolerated
V107fs indel 0.001 0 frameshift stop codon stop codon
G113V G.T 0 0.001 NS possibly damaging tolerated
F139F (rs12328317) C.T 0.001 0.001 S - -
L153V (rs35050588) C.G 0.001 0 NS benign tolerated
L161P T.C 0.001 0 NS benign tolerated
G171S G.A 0.001 0 NS benign tolerated
P179P C.T 0.001 0 S - -
G180G (rs35658907) C.T 0.026 0.034 S - -
G180S G.A 0 0.001 NS benign tolerated
Y194Y C.T 0.001 0 S - -
M197T T.C 0.001 0 NS possibly damaging affected
E211Q G.C 0.001 0 NS benign tolerated
R225W C.T 0.001 0.001 NS probably damaging affected
R225Q G.A 0 0.001 NS benign tolerated
Q260R A.G 0.001 0.006 NS benign tolerated
I269T T.C 0.001 0 NS possibly damaging affected
R307C C.T 0.001 0 NS probably damaging affected
P313P G.A 0.001 0.001 S - -
R340W (rs33985460) C.T 0.053 0.056 NS probably damaging affected
R340Q G.A 0.001 0 NS benign tolerated
R446M G.T 0 0.001 NS possibly damaging tolerated
A482V (rs34720726) C.T 0.002 0 NS benign affected
D485N G.A 0.005 0.001 NS benign tolerated
L487L C.T 0.001 0 S - -
(MAF: minor allele frequency; S/NS: synonymous/nonsynonymous)
doi:10.1371/journal.pone.0000903.t002
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R225Qc3 mice [37,38], it is anticipated that the human R225W
variant would result in improved capacity during chronic exercise
challenges due to their increased muscle glycogen. The natural
occurrence of mutations in AMPKc3 was first discovered in
Hampshire RN
- pigs [26,34]. The single missense mutation,
arginine 225 to glutamine (R225Q) results in a dominant mutation
that is homologous to the c3 R225W variant described here.
R225Q causes an approximate 70% increase in skeletal muscle
glycogen, but no change in heart and liver glycogen content,
resulting in poor meat quality. Other phenotypic effects include
lower muscle fat content and increased oxidative capacity.
Furthermore, Hampshire RN
- pigs carrying the mutation showed
normal resting levels of glucose and insulin as well as normal
glucose tolerance tests. When challenged with exercise, it was
found that R225Q pigs depleted their glycogen stores at normal
rates, but re-synthesized glycogen at faster rates than control pigs
due to increased muscle glucose uptake rates [34,35]. This limited
evidence indicated no functional impairments associated with the
increased glycogen in skeletal muscle. Our findings that human
R225W carriers have an approximate 90% increase in skeletal
muscle glycogen, an approximate 30% decrease in intramuscular
triglyceride, and normal levels of plasma lipids, glucose, insulin
and HbA1C are consistent with the animal studies described
above. Future studies will investigate the physiological response of
these subjects to exercise challenges.
Recently mice bearing the homologous human AMPK c3
transgene, Tg-R225Q, were developed to study the effects of the
naturally occurring pig mutation. The R225Q mutation produced
a fully dominant protein [7] with increased AMPK activity. ACC
phosphorylation was increased in the basal state as well as after
stimulation with AICAR (an artificial activator of AMPK),
indicating that the mutated AMPK could be activated [7].
Glycogen content of various muscles in mice bearing the R225Q
mutation have 1.5–2 times the glycogen content of controls [36],
consistent with our findings in humans. Moreover, exercise
increased ACC phosphorylation and decreased intramuscular
triglyceride (IMTG) in the gastrocnemius muscle of transgenic,
compared to wild-type, mice. Tg-R225Q mice thus oxidized more
fat in the AMP-stimulated state (during exercise) compared to
wild-type controls [38]. As demonstrated in the current study, the
R225Wc3 mutation in humans is a gain-of-function mutation that
exhibits increased basal and AMP-activated activity of AMPK. It
should be noted that total cellular AMPK activity was assayed in
this study, not immuno-purified c3 activity. Therefore, the R225W
mutation in c3 has an important effect overall on total AMPK
activity in skeletal muscle. It will be of interest in future studies to
determine whether the a1b2c1, a2b2c1 and a2b2c3 subunit
combinations normally found in human vastus lateralis are also
formed in skeletal muscle of R225W carriers.
Interestingly, this novel mutation is analogous to the c2 subunit
mutation that causes inherited cardiac arrhythmias and cardiac
hypertrophy [21,24,25]. While it is known that AMPK activity
stimulates fatty acid oxidation, glucose uptake and glycolysis in the
heart, its regulation is complex, and still not well understood [22].
Missense mutations within the CBS domains of c2 have been
shown to cause the excess storage of glycogen in pronounced
glycogen-associated vacuoles [23]. This excess storage of glycogen
is thought to result in myocyte hypertrophy, and gives rise to
WPW syndrome and cardiac conduction disease [23]. The
enhanced skeletal muscle glycogen deposition demonstrated in
carriers of the analogous c3 mutation is consistent with the above
results in the heart. Subsequent introduction of some of the c2
mutations into the AMPK homologue in yeast (SNF1/SNF4)
produced a constitutively active enzyme, indicating that these
heterozygous missense mutations were dominant in their effect
[25]. Our findings indicate that the c3 R225W mutation increases
basal AMPK activity, but results in a protein that can be further
activated by AMP, unlike the latter c2 mutations.
In summary, we report the identification of human subjects
bearing a R225W mutation in PRKAG3 which causes increased
basal and AMP-stimulated AMPK activity, increased glycogen
content and decreased IMTG in skeletal muscle. These findings
are relevant to an improved understanding of the regulatory role
that AMPK plays in skeletal muscle energy metabolism. The c3
subunit represents an attractive pharmacological target due to its
exclusive expression in skeletal muscle. It has already been
demonstrated that Metformin, commonly prescribed for treatment
of type 2 diabetes, acts via stimulation of AMPK [39–41]; and
although it is not possible to draw conclusions regarding
therapeutics from this study, it is tempting to hypothesize that
the stimulation of AMPK activity in skeletal muscle alone, without
affecting AMPK activity in the brain or heart, could be effective in
the treatment of obesity and type 2 diabetes mellitus.
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